In a decision last Thursday, the Federal Circuit made a ruling that effectively thwarts Alvogen’s plans to release a generic variant of Bausch Health’s successful diarrhea and brain disease medication, Xifaxan, until 2029. Alvogen’s attempt to initiate an earlier launch was dismissed despite the company having been acquitted of some patent infringements.
Xifaxan, a major product of Bausch Health, has been a significant player in the world of diarrhea and brain disease medications. The current decision of the Federal Circuit to uphold the release date of Alvogen’s generic version effectively prolongs Bausch Health’s exclusive marketing rights over the drug until at least 2029.
The reason for the rejection of Alvogen’s bid for an early launch boils down to the specifics of patent law. Despite having obtained clearance over some patents, it appears that the company has not managed to bypass all necessary legal hurdles, leading to the current indefinite postponement.
Both corporate law firms and pharmaceutical corporations are likely to pay close attention to this case, as the outcome could set substantive precedent for future cases involving intellectual property rights in the field of generic drugs. For more detailed information about this case and its potential implications on the industry, visit Law360.